IN THE SPECIFICATION:

Please disregard the reply filed on 5/14/01 (paper #20).

Please disregard the statement "On Page 10, lines 11 and 12, please delete [R]" in the previous amendment (filed 11/18/00), and instead, please amend as follows:

On page 11, lines 10-12, please delete [R]. The new paragraph should read:

In one embodiment, the prosaposin receptor agonist useful in the invention is a prosaposin receptor agonist of 14 to 50 amino acids which has the amino acid sequence $LIRX_1NN$ $X_2T X_3 X_4 X_3 X_1 X_1$, where X_1 is any amino acid; X_2 is any amino acid, but not L or R; X_3 is a charged amino acid; and X_4, when present, is a charged amino acid.

IN THE CLAIMS:

Please amend claim 4 as follows and substitute it for the previously amended (reply filed 11/18/00) claim 4.

4. (Twice amended) A pharmaceutical composition <u>for treating neuropathic pain,</u> comprising:

[the]<u>a</u> prosaposin receptor agonist <u>consisting</u> of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in <u>an effective amount that is greater than 20 µg/ kg and less than 100 µg/kg of body weight;</u> and

a pharmaceutically acceptable carrier.

The amended claim should be:

4. A pharmaceutical composition for treating neuropathic pain, comprising:

a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in an effective amount that is greater than 20 µg/ kg and less than 100 µg/kg of body weight; and

a pharmaceutically acceptable carrier.

2